REFERENCES

1. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693-9.

2. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394-403.

3. Sugawara Y, Tamura S, Makuuchi M. Living donor liver transplantation for hepatocellular carcinoma: Tokyo University series. Dig Dis 2007;25:310-12.

4. Lee SG, Hwang S, Moon DB, Ahn CS, Kim KH, et al. Expanded indication criteria of living donor liver transplantation for hepatocellular carcinoma at one large-volume center. Liver Transpl 2008;14:935-45.

5. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009;10:35-43.

6. Ito T, Takada Y, Ueda M, Haga H, Maetani Y, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl 2007;13:1637-44.

7. Toso C, Asthana S, Bigam DL, Shapiro AM, Kneteman NM. Reassessing selection criteria prior to liver transplantation for hepatocellular carcinoma utilizing the scientific registry of transplant recipients database. Hepatology 2008;49:832-8.

8. Taketomi A, Sanefuji K, Soejima Y, Yoshizumi T, Uchiyama H, et al. Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009;87:531-7.

9. DuBay D, Sandroussi C, Sandhu L, Cleary S, Guba M, et al. Liver transplantation for advanced hepatocellular carcinoma using poor tumor differentiation on biopsy as an exclusion criterion. Ann Surg 2011;253:166-72.

10. Kim JM, Kwon CH, Joh JW, Park JB, Lee JH, et al. Expanded criteria for liver transplantation in patients with hepatocellular carcinoma. Transplant Proc 2014;46:726-9.

11. Llovet JM. Expanding HCC criteria for liver transplant: the urgent need for prospective, robust data. Liver Transpl 2006;12:1741-3.

12. Duvoux C, Roudot Thoraval F, Decaens T, Pessione F, et al. Liver transplantation for hepatocellular carcinoma: a model including α-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986-94.

13. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol 2017;3:493-500.

14. Lai Q, Nicolini D, Inostroza Nunez M, Iesari S, Goffette P, et al. A novel prognostic index in patients with hepatocellular cancer waiting for liver transplantation: Time-Radiological-response-Alpha-fetoprotein-INflammation (TRAIN) score. Ann Surg 2016;264:787-96.

15. Lee JH, Cho Y, Kim HY, Cho EJ, Lee DH, et al. Serum tumor markers provide refined prognostication in selecting liver transplantation candidate for hepatocellular carcinoma patients beyond the Milan criteria. Ann Surg 2016;263:842-50.

16. Halazun KJ, Hardy MA, Rana AA, Woodland DC 4th, Luyten EJ, et al. Negative impact of neutrophil-lymphocyte ratio on outcome after liver transplantation for hepatocellular carcinoma. Ann Surg 2009;250:141-51.

17. Zheng J, Cai J, Li H, Zeng K, He L, et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review. Cell Physiol Biochem 2017;44:967-81.

18. Hong G, Suh KS, Suh SW, Yoo T, Kim H, et al. Alpha-fetoprotein and (18)F-FDG positron emission tomography predict tumor recurrence better than Milan criteria in living donor liver transplantation. J Hepatol 2016;64:852-9.

19. Takada Y, Kaido T, Shirabe K, Nagano H, Egawa H, et al. Significance of preoperative fluorodeoxyglucose-positron emission tomography in prediction of tumor recurrence after liver transplantation for hepatocellular carcinoma patients: a Japanese multicenter study. J Hepatobiliary Pancreat Sci 2017;24:49-57.

20. Nakao K, Ichikawa T. Recent topics on alpha-fetoprotein. Hepatol Res 2013;43:820-5.

21. Cillo U, Giuliani T, Polacco M, Herrero Manley LM, Crivellari G, et al. Prediction of hepatocellular carcinoma biological behavior in patient selection for liver transplantation. World J Gastroenterol 2016;22:232-52.

22. Kobayashi T, Aikata H, Honda F, Nakano N, Nakamura Y, et al. Preoperative fluorine 18 fluorodeoxyglucose positron emission tomography/computed tomography for prediction of microvascular invasion in small hepatocellular carcinoma. J Comput Assist Tomogr 2016;40:524-30.

23. Imura S, Teraoku H, Yoshikawa M, Ishikawa D, Yamada S, et al. Potential predictive factors for microvascular invasion in hepatocellylar carcinoma classified within the Milan criteria. Int J Clin Oncol 2018;23:98-103.

24. Shimamura T, Akamatsu N, Fujiyoshi M, Kawaguchi A, Morita S, et al. Expanded living-donor liver transplantation criteria for patients with hepatocellular carcinoma based on the Japanese nationwide survey: the 5-5-500 rule - a retrospective study. Transpl Int 2019;32:356-68.

25. Kokudo N, Sugawara Y, Imamura H, Sano K, Makuuchi M. Tailoring the type of donor hepatectomy for adult living donor liver transplantation. Am J Transplant 2005;5:1694-703.

26. Akamatsu N, Sugawara Y, Kaneko J, Arita J, Sakamoto Y, et al. Low platelet counts and prolonged prothrombin time early after operation predict the 90 days morbidity and mortality in living-donor liver transplantation. Ann Surg 2017;265:166-72.

27. Furukawa H, Shimamura T, Suzuki T, Taniguchi M, Nakanishi K, et al. Liver transplantation for hepatocellular carcinoma: the Japanese experience. J Hepatobiliary Pancreat Sci 2010;17:533-8.

28. Tamura S, Sugawara Y, Kokudo N. Living donor liver transplantation for hepatocellular carcinoma: the Japanese experience. Oncology 2011;81:111-5.

29. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11-22.

30. Todo S, Furukawa H, Tada M. Extending indication: role of living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2007;13:S48-54.

31. Mailey B, Artinyan A, Khalili J, Denitz J, Sanchez-Luege N, et al. Evaluation of absolute serum α-fetoprotein levels in liver transplant for hepatocellular cancer. Arch Surg 2011;146:26-33.

32. Berry K, Ioannou GN. Serum alpha-fetoprotein level independently predicts posttransplant survival in patients with hepatocellular carcinoma. Liver Transpl 2013;19:634-45.

33. Zheng SS, Xu X, Wu J, Chen J, Wang WL, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences. Transplantation 2008;85:1726-32.

34. Wongjarupong N, Negron-Ocasio GM, Chaiteerakij R, Addissie BD, Mohamed EA, et al. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models. World J Gastroenterol 2018;24:1321-31.

35. Tamura Y, Igarashi M, Kawai H, Suda T, Satomura S, et al. Clinical advantage of highly sensitive on-chip immunessay for fucosylated fraction of alpha-fetoprotein in patients with hepatocellular carcinoma. Dig Dis Sci 2010;55:3576-83.

36. Hanaoka T, Sato S, Tobita H, Miyake T, Ishihara S, et al. Clinical significance of the highly seisitive fucosylated fraction of alpha-fetoprotein in patients with chronic liver disease. J Gastroenterol Hepatol 2011;26:739-44.

37. Toyoda H, Kumada T, Tada T. Highly sensitive Lens clinaris agglutinin-reactive alpha-fetoprotein: a new tool for the management of hepatocellular carcinoma. Oncology 2011;81:61-5.

38. Olthoff KM, Goldberg DS. The MoRAL path beyond Milan. Ann Surg 2016;263:851-2.

39. Shirabe K, Itoh S, Yoshizumi T, Soejima Y, Taketomi A, et al. The predictors of microvascular invasion in candidates for liver transplantation with hepatocellular carcinoma-with special reference to the serum levels of des-gamma-carboxy prothrombin. J Surg Oncol 2007;95:235-40.

40. Rosenblatt RE, Tafesh ZH, Halazun KJ. Role of inflamematory markers as hepatocellular cancer selection tool in the setting of liver transplantation. Transl Gastroenterol Heaptol 2017;2:95.

41. Citores MJ, Lucena JL, de la Fuente S, Cuervas-Mons V. Serum biomarkers and risk of hepatocellular carcinoma recurrence after liver transplantation. World J Hepatol 2019;11:50-64.

42. Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story. Ann Surg 2017;265:557-64.

43. Mazzaferro V, Citterio D, Bhoori S, Bongini M, Miceli R, et al. Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial. Lancet Oncol 2020;21:947-56.